Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201712-14 Development of next generation vaccine against respiratory viral diseases(Infectious Diseases, Protein) [2019-08-29]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Influenza virus surface proteins in monomeric forms and those in fusion forms with self-assembled molecular scaffold will be validated as novel universal influenza vaccines. Compared to conventional vaccines with trimeric antigens, our approach will provide a creative platform to offer conserved epitope with global competitiveness, which will control virus strains in various subtypes and potential new pandemic strains.

Unmet Medical Need & Target Patients

Vaccines are the most effective means to prevent infectious diseases. However, influenza viruses have high mutation and recombination rates producing new virus strains and subtypes, which causes a major problem for reduced vaccine efficacy. Antiviral resistant influenza strains have also spread globally. Moreover, it takes 4-6 months to develop vaccine strains in eggs whose supply should meet the needs of a pandemic and whose safety issues include egg allergy.

Status

Monomer antigens are prepared for influenza virus H1, H3, and B hemagglutinin to be characterized and examined for their immunogenicities in in vivo experiments. Protein engineering, expression, purification, and characterization of the antigens are now performed in in vitro experiments, and the immunogenicities of monomeric antigens will be compared with those of trimeric antigens and commercial vaccines in in vivo studies .

Intellectual Property

ANTIGEN COMPOSITION AGAINST ORTHOMYXOVIRUSES COMPRISING INFLUENZA VIRUS SURFACE PROTEIN HEMAGGLUTININ MONOMER (2016).

This property includes an intellectual right for monomeric forms of surface proteins in orthomyxoviruses, which provide conserved epitopes.

Competitive Advantages

First, monomeric and fusion forms of antigens will provide broad-spectrum protection against divergent influenza viruses, which will overcome the disadvantage of current vaccination every year. Second, recombinant protein-based platform technology is established to provide universal vaccines in a short period of time. Third, the fusion forms of multi-antigens based on a scaffold will enhance epitope density and organization, which will increase antigen immunogenicity.  

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code